SALEKI-GERHARDT AZITA 4
4 · AbbVie Inc. · Filed Feb 18, 2025
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
SALEKI-GERHARDT AZITA
EVP, CHIEF OPERATIONS OFFICER
Transactions
- Award
Common Stock, $0.01 par value
2025-02-13+17,986→ 212,334 total - Award
Common Stock, $0.01 par value
2025-02-13+6,060→ 225,772 total - Award
Common Stock, $0.01 par value
2025-02-13+7,074→ 232,846 total - Award
Common Stock, $0.01 par value
2025-02-13+7,378→ 219,712 total - Award
Option (Right to Buy)
2025-02-13+25,000→ 25,000 totalExercise: $192.86Exp: 2035-02-12→ Common Stock (25,000 underlying)
Holdings
- 2,601(indirect: By Trust)
Common Stock, $0.01 par value
- 3,873(indirect: By Trust)
Common Stock, $0.01 par value
Footnotes (7)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F5]Balance in AbbVie Savings program as of January 31, 2025. Balance includes shares acquired pursuant to a dividend reinvestment feature.
- [F6]The reporting person disclaims beneficial ownership of all securities held by her spouse.
- [F7]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on February 13, 2026, 8,333 on February 13, 2027, and 8,333 on February 13, 2028.